Purpose of Review This scoping review aims to evaluate the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in the context of musculoskeletal healing. Given the compound’s increasing availability, popularity, and its regulatory controversies, we sought to assess the breadth and quality of preclinical and clinical data supporting its use in musculoskeletal medicine. Recent Findings BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regenerative properties across numerous animal models. It activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization. It also engages ERK1/2 signaling, facilitates endothelial and muscle repair, and exerts anti-inflammatory effects. These effects promote angiogenesis, fibroblast activity, and neuromuscular stabilization, particularly in poorly vascularized tissues such as tendons and myotendinous junctions. Despite broad preclinical support, human data are extremely limited. Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported, but rigorous, large-scale trials are lacking. BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in musculoskeletal medicine. Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available. Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution. This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine.
Diagram illustrating the molecular mechanisms by which BPC-157 promotes tissue regeneration, cytoprotection, and neuromodulation. BPC-157 activates VEGF-dependent (via VEGFR2–PI3K–Akt–eNOS) and VEGF-independent (via Src–caveolin-1–eNOS) pathways to NO production, supporting angiogenesis, vasodilation, and vascular stability. It upregulates cytoprotective factors such as heme oxygenase-1 (HO-1) and heat shock proteins, preserving mitochondrial integrity and reducing oxidative stress. BPC-157 also restores glutamatergic signaling after NMDA receptor overactivation (e.g., ketamine, MK-801 exposure) and modulates adrenergic balance by counteracting beta-adrenergic overstimulation and blockade, preventing vascular occlusion-like syndromes. In endothelial cells, BPC-157 activates ERK1/2 signaling, enhancing proliferation, migration, and vascular tube formation through transcription factors like c-Fos, c-Jun, and Egr-1; ERK1/2 activation is required for its pro-healing effects both in vitro and in vivo, including in alkali-burn wound models
...
Figures - available from: Current Reviews in Musculoskeletal Medicine
This content is subject to copyright. Terms and conditions apply.
Discover the world's research
25+ million members 160+ million publication pages 2.3+ billion citations
Join for free
REVIEW
Current Reviews in Musculoskeletal Medicine (2025) 18:611–619
https://doi.org/10.1007/s12178-025-09990-7
Introduction
Peptide therapy is an emerging area of research in musculo-
skeletal medicine. Peptides, naturally occurring short chains
of amino acids synthesized in the body, act as selective sig-
naling molecules that bind to specic cell surface receptors,
triggering intracellular cascades [1]. Peptides play a crucial
role in various biological functions and have been widely
applied in drug development over the past decade [2]. Given
their ability to regulate physiological mechanisms, research
has increasingly focused on harnessing naturally-occurring
peptides to develop new therapeutic tools [3]. Among pep-
tides studied for tissue and muscle repair [4, 5], BPC-157
(also known as PLD-116, PL-10, PL14736, or Bepectin
[6–9]) has gained attention [10, 11]. Originally isolated
from human gastric juice by Dr. Predrag Sikiric in 1993,
Flynn P. McGuire
1 Department of Physical Medicine & Rehabilitation,
University of Utah, Salt Lake City, UT 84108, USA
2 Department of Pediatrics, University of Utah, Salt Lake City,
UT 84108, USA
3 Department of Physical Therapy, University of Utah, Salt
Lake City, UT 84108, USA
4 Department of Orthopaedics, University of Utah, Salt Lake
City, UT 84108, USA
Abstract
Purpose of Review This scoping review aims to evaluate the molecular mechanisms, therapeutic potential, and safety con-
cerns of Body Protective Compound-157 (BPC-157) in the context of musculoskeletal healing. Given the compound’s
increasing availability, popularity, and its regulatory controversies, we sought to assess the breadth and quality of preclinical
and clinical data supporting its use in musculoskeletal medicine.
Recent Findings BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regen-
erative properties across numerous animal models. It activates several overlapping pathways, notably VEGFR2 and nitric
oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, broblast activity, and neuromuscular stabilization. It also
engages ERK1/2 signaling, facilitates endothelial and muscle repair, and exerts anti-inammatory eects. These eects pro-
mote angiogenesis, broblast activity, and neuromuscular stabilization, particularly in poorly vascularized tissues such as
tendons and myotendinous junctions. Despite broad preclinical support, human data are extremely limited. Only three pilot
studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous
safety/pharmacokinetics. No adverse eects were reported, but rigorous, large-scale trials are lacking.
Summary BPC-157 demonstrates robust regenerative and cytoprotective eects in preclinical studies, positioning it as a
potentially valuable tool in musculoskeletal medicine. Despite its growing popularity among athletes and its wide availabil-
ity through non-regulated sources, there is minimal human data available. Until well-designed clinical trials are conducted,
BPC-157 should be considered investigational, and its use approached with caution. This review highlights that given the
robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety,
ecacy, and clinical utility of BPC-157 in musculoskeletal medicine.
Keywords Pentadecapeptide · Scoping review · Musculoskeletal medicine · Research gaps
Accepted: 31 July 2025 / Published online: 12 August 2025
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025
Regeneration or Risk? A Narrative Review of BPC-157 for
Musculoskeletal Healing
Flynn P.McGuire1· RileyMartinez1· AnnikaLenz2· LeeSkinner3· Daniel M.Cushman1,4
1 3
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
... A fourth group includes experimental or wellness peptides promoted online despite limited, inconsistent, or nongeneralizable human evidence. This group includes compounds such as BPC-157, CJC-1295, ipamorelin, GHK-Cu, MOTS-c, semax, selank, and TB-500, several of which have been flagged by regulators or discussed in the literature as areas of uncertain safety, limited evidence, or nonapproved use [21,31,32]. Table 1 summarizes these tiers. ...
... MOTS-c; epitalon; semax; selank [21,31,32]. ...
... Online visibility may exceed human evidence and safety characterization [21,31,32]. ...
... IA injection of peptide that affects ERK 1/2, VEGF2-NO, and FAK-paxillin signaling pathways, resulting in increased angiogenesis, fibroblast activity, collagen synthesis, and anti-inflammation [84]. ...
... The ERK 1/2 pathway promotes endothelial and muscle repair, induces angiogenesis and fibroblast activity, and exerts anti-inflammatory effects. VEGF2-NO pathway also promotes angiogenesis and fibroblast activity, while the FAK-paxillin pathway is responsible for fibroblast proliferation and collagen synthesis, making BPC-157 useful in musculoskeletal repairs and performance enhancement [84]. While BPC-157 is known to have a short half-life, often cited as less than 30 min, its effect in animal studies has been shown to persist for weeks to months [103][104][105][106]. ...
... These sustained effects are believed to be due to the activation of multiple gene expression pathways, as mentioned before, which can continue independently. Therefore, this peptide can potentially serve as a catalyst in triggering self-sustaining healing mechanisms present in our bodies without the need for recurrent injuries or inflammation [84]. ...
Woojin Lee Qing Zhao Ruan Jamal J. Hasoon Christopher L. Robinson
As the population ages, the incidence and prevalence of musculoskeletal degeneration, such as osteoarthritis, increase. While the currently accepted treatment options provide symptomatic and functional improvement, they do not halt the progression of osteoarthritis. This results in the eventual need for surgery for many patients with advanced osteoarthritis. Due to the seemingly inevitable progression of OA, many clinicians and researchers have shifted their focus to regenerative therapies. Orthobiologics, a specific type of regenerative therapy designed to treat orthopedic conditions, has been gaining traction in recent years due to the utilization of autologous biological substances and synthetic peptides in healing musculoskeletal injuries and degenerative conditions. Orthobiologics can be distinguished into one of four classes: cell-based, biologic fluids-based, matrix-based, molecular-based, and based on their composition. In this review, key examples of each class, mechanism of action, and current clinical data for each agent are examined. Limitations of current orthobiologics involve a lack of standardization in the preparation and administration of each agent, as well as uniformity in assessment endpoints across different clinical studies. Lastly, we will discuss future directions of orthobiologics as a therapy for the treatment of osteoarthritis. Keywords: knee osteoarthritis, orthobiologics, regenerative medicine, platelet-rich plasma
... In recent years, the experimental peptide BPC-157 (Body Protection Compound-157) has sparked immense interest in the fields of sports medicine and orthopaedics. It is a synthetic, 15amino acid fragment of a protein naturally found in human gastric juice, which exhibits extraordinarily strong regenerative properties for musculoskeletal tissues [24,29]. Preclinical studies in animal models demonstrate that the administration of BPC-157 accelerates the healing of both soft tissues and bone, including in challenging segmental defect models, where it stimulated the formation of mature lamellar bone instead of fibrous tissue [29]. ...
... Preclinical studies in animal models demonstrate that the administration of BPC-157 accelerates the healing of both soft tissues and bone, including in challenging segmental defect models, where it stimulated the formation of mature lamellar bone instead of fibrous tissue [29]. The primary mechanism of action of this peptide relies on the potent stimulation of angiogenesis-a critical process for restoring blood supply in the ischemic fracture site-and the promotion of the survival and proliferation of local cells (e.g., fibroblasts and osteoblasts) [24,29]. Despite highly promising in vivo results, the use of BPC-157 in humans remains controversial. ...
... Despite highly promising in vivo results, the use of BPC-157 in humans remains controversial. There is currently a lack of rigorous, randomized clinical trials on patients, which means this substance is not officially approved for the treatment of injuries and is currently on the World Anti-Doping Agency (WADA) prohibited list [24,29]. ...
Bartosz Machnio Agata Świątek Kamil Andruszkiewicz Julia Bąk
Introduction and purpose: Bone fractures and healing complications, such as delayed union and non-union, present a substantial and growing global healthcare burden. While surgical fixation techniques have advanced significantly, optimizing the biological environment through targeted nutritional and pharmacological interventions remains critical for successful osteogenesis. This review aims to systematize the current knowledge regarding the impact of exogenous supplementation and adjuvant pharmacotherapy - ranging from basic nutrients to advanced biological drugs - on the bone fracture healing process. A brief description of the state of knowledge: Based on a comprehensive literature search of major medical databases focusing on the last 15 years, the synthesis of clinical and preclinical data indicates that correcting baseline nutritional deficiencies (particularly protein, amino acids, and vitamin D3) is an essential prerequisite for adequate soft callus formation and subsequent mineralization. Structural components like chondroitin sulphate and collagen, alongside phytotherapeutics such as Cissus quadrangularis, provide significant early-stage support for endochondral ossification. Conversely, routine administration of non-steroidal anti-inflammatory drugs (NSAIDs) during the acute inflammatory phase should be approached with high caution due to their potential to significantly delay healing. In recalcitrant cases, advanced therapies like systemic teriparatide and locally applied bone morphogenetic proteins (BMPs) offer potent osteoinductive rescue strategies. Summary (conclusions): A multifaceted approach that integrates early nutritional optimization, judicious analgesic management, and targeted osteoinductive pharmacotherapy is vital for enhancing physiological bone repair, reducing recovery time, and preventing severe non-union complications.
... Preclinical studies also suggest that BPC-157 exhibits antioxidant and anti-inflammatory activity, including modulation of cytokine signaling involved in tissue injury and repair. 36,38 However, current evidence for BPC-157 derives largely from animal models and early translational research focused on gastrointestinal and musculoskeletal healing. Thyroid-specific clinical data remain limited, and additional controlled studies are required to determine whether the observed regenerative and immunomodulatory properties of BPC-157 translate into meaningful therapeutic benefit in thyroid disease. ...
... 8 Additionally, BPC-157 has been shown to modulate macrophage polarization and dendritic cell signaling, further contributing to a regulatory immune milieu favorable to thyroid preservation. 38 Mitochondrial integrity and oxidative balance are critical determinants of thyroid hormone synthesis and cellular responsiveness to triiodothyronine. Oxidative stress has been implicated as both a consequence and a contributing factor in thyroid dysfunction, where excess reactive oxygen species may promote epithelial injury and immune activation within the gland. ...
Angela Mazza
... BPC-157, a stable gastric pentadecapeptide (Figure 1), has been extensively studied for its cytoprotective, anti-inflammatory, and regenerative effects [9][10][11]. Importantly, it has also been shown to preserve neuromuscular function by stabilizing acetylcholine receptors and nerve terminals at the neuromuscular junction [12,13], suggesting its role in modulating cholinergic signaling. However, despite these observations, its potential to directly affect acetylcholinesterase activity has not been previously investigated. ...
Juliana Jelińska Michalina Józwiak
Łukasz Szeleszczuk Błażej Grodner
Acetylcholinesterase (AChE) inhibition remains a key therapeutic strategy in the management of neurodegenerative disorders such as Alzheimer’s disease. In this study, the inhibitory potential of the gastric pentadecapeptide BPC-157 and two newly designed hybrid analogs, CIARA-1 and CIARA-2, was investigated for the first time. The hybrid peptides were rationally designed by combining a BPC-157-derived fragment with an arginine-containing C-terminal sequence to enhance interactions with the enzyme’s active and peripheral binding sites. Enzyme kinetics were evaluated using a modified Ellman assay, and inhibition parameters were determined through Lineweaver–Burk analysis. All tested compounds exhibited a competitive mechanism of inhibition, as evidenced by increased Michaelis–Menten constant (Km) values with unchanged maximum velocity (Vmax), indicating competition with the substrate at the catalytic site of AChE. Among the tested compounds, CIARA-1 demonstrated the highest inhibitory potency, reflected by the lowest inhibition constant (Ki = 0.24 mM) and IC50 value (2.52 mM), followed by CIARA-2 (Ki = 0.29 mM; IC50 = 2.73 mM) and BPC-157 (Ki = 0.48 mM; IC50 = 2.80 mM). These findings were consistent with molecular modeling predictions, supporting stronger binding interactions for CIARA-1. Despite significantly lower potency compared to clinically used AChE inhibitors, the studied peptides represent a promising scaffold for further optimization. Overall, this work demonstrates that BPC-157 and its hybrid analogs act as reversible competitive AChE inhibitors, with enhanced activity observed for structurally modified derivatives. The results highlight the potential of peptide-based hybrid molecules as multifunctional candidates in the development of novel therapeutics targeting cholinergic dysfunction.
Chantal Nguyen Matthew R Allen Kalvis Hornburg
Michael Fredericson
Supplementation use in athletes is common and increasing in popularity, especially for adults seeking improvements in athletic performance. However, the effects of supplementation for older adults or Masters athletes in improving athletic performance or musculoskeletal health are less well explored. The aim of this narrative review is to explore common supplements, namely protein, caffeine, creatine, beta-alanine, nitrates, and peptides, including collagen, body protection compound-157, and thymosin-beta 4 and 500, in improving performance or musculoskeletal health in Masters athletes and adults over 55 years of age.
Timothy Piatkowski
Kyle T. Ganson
Jason M Nagata
This Viewpoint discusses the growing presence of synthetic peptides in enhancement drug use and outlines regulatory gaps created by the blurring of boundaries between medicine and illicit use.
Ivan Smoday
Vlasta Vuković Katarina Oroz
Anita Skrtic
Background. This rat study reveals a new point: the considerable impact of unilateral adrenalectomy, severe vascular and multiorgan failure, occlusion/occlusion-like syndrome, and the stable gastric pentadecapeptide BPC 157 therapy. Based on the recent Fourier transform infrared (FTIR) spectroscopy vascular disturbance studies, particularly those after unilateral adrenalectomy in rats, the noted cytoprotective vascular recovery effect of the BPC 157 therapy may be useful. Methods. In rats, unilateral adrenalectomy (at 15 min, 5 h, 24 h) leads to integrated gross and morphological changes, vascular alterations, oxidative stress parameters, molecular markers and occlusion/occlusion-like syndrome and BPC 157 as useful therapy (/kg ig) (10 μg, 10 ng). Results. Peripherally and centrally, counteraction includes the lesions (adrenal, brain, heart, lung, liver, kidney, gastrointestinal tract), organ hemorrhage, and thrombosis. Attenuated/eliminated were arrhythmias, intracranial (superior sagittal sinus), portal, caval hypertension, and aortic hypotension. Significant resolution occurred via activation of collateral pathways, the azygos vein (direct blood flow delivery), and the recovered peduncle of the inferior suprarenal artery and superior suprarenal vein. Virchow’s triad circumstances were reversed. Occlusion/occlusion-like syndrome was counteracted as a whole. Also, BPC 157 counteracted adrenal lesions (lipid depletion, congestion). There were higher cortisol values, but still very low, and a shift toward the left of the adrenal compensatory weight increase. For the indicative conclusion along with previous studies, mechanistically, BPC 157 therapy exhibits the NO-system modulation/oxidative stress balance, increases NO-level, counteracts oxidative stress (malondialdehyde (MDA)), upregulates NOS1–3, and VEGF-A expression. Conclusions. These effects of BPC 157 therapy and its easy applicability deserve further consideration.
Hüseyin Demirtaş Abdullah Özer
Alperen Kutay Yıldırım
Mustafa Arslan
Background and Objectives: Ischemia–reperfusion (I/R) injury can affect multiple distant organs following I/R in the lower extremities. BPC-157’s anti-inflammatory and free radical-neutralizing properties suggest its potential in mitigating ischemia–reperfusion damage. This study evaluates the protective effects of BPC-157 on remote organ damage, including the kidneys, liver, and lungs, in a rat model of skeletal muscle I/R injury. Materials and Methods: A total of 24 male Wistar albino rats were randomly divided into four groups: sham (S), BPC-157(B), lower extremity I/R(IR) and lower extremity I/R+BPC-157(I/RB). Some 45 min of ischemia of lower extremity was followed by 2 h of reperfusion of limbs. BPC-157 was applied to groups B and I/RB at the beginning of the procedure. After 2 h of reperfusion, liver, kidney and lung tissues were harvested for biochemical and histopathological analyses. Results: In the histopathological examination, vascular and glomerular vacuolization, tubular dilation, hyaline casts, and tubular cell shedding in renal tissue were significantly lower in the I/RB group compared to other groups. Lung tissue showed reduced interstitial edema, alveolar congestion, and total damage scores in the I/RB group. Similarly, in liver tissue, sinusoidal dilation, necrotic cells, and mononuclear cell infiltration were significantly lower in the I/RB group. Additionally, the evaluation of TAS, TOS, OSI, and PON-1 revealed a statistically significant increase in antioxidant activity in the liver, lung, and kidney tissues of the I/RB group. Conclusions: The findings of this study demonstrate that BPC-157 exerts a significant protective effect against distant organ damage in the liver, kidneys, and lungs following lower extremity ischemia–reperfusion injury in rats.
Michalina Józwiak Marta Bauer Wojciech Kamysz
Patrycja Kleczkowska
BPC 157, known as the “Body Protection Compound”, is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory bowel disease, or even CNS disorders. Unlike many other drugs, BPC 157 has a desirable safety profile, since only a few side effects have been reported following its administration. Nevertheless, this compound was temporarily banned by the World Anti-Doping Agency (WADA) in 2022 (it is not currently listed as banned by the WADA). However, it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans. In this review, we summarize information on the biological activities of BPC 157, with particular reference to its mechanism of action and probable toxicity. This generated the attention of experts, as BPC 157 has been offered for sale on many websites. We also present recent interest in BPC 157 as reflected in a number of patent applications and granted patents.
Danijel Matek Irena Matek Eva Staresinic Ivica Brizic
Background: This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration. Methods: Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 μg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles). Results: Immediately post-injury, and at 1, 2, 3, 5, 7, 14, 21, 28, 60, and 90 days post-injury, quadriceps muscle-to-bone detachment showed definitive healing failure (impaired walking and permanent knee flexure). Contrarily, macro/microscopic, ultrasonic, magnetic resonance, biomechanical, and functional assessments revealed that BPC 157 therapy recovering effects for all time points were consistent. All parameters of the walking pattern fully improved, and soon after detachment and therapy application, muscle approached the bone, leaving a minimal gap (on ultrasonic assessment), and leg contracture was annihilated. The healing process occurs immediately after detachment from both sides: the muscle and the bone. The reattachment fibers from the ends of the muscle could be traced into the new bone formed at the surface (note, at day 3 post-detachment, increased mesenchymal cells occurred with periosteum reactivation). Consequently, at 3 months, the form was stable, and the balance between the muscle and bone was the following: well-organized bone, newly formed as more cortical bone providing a narrower bone marrow space, and the muscle and mature fibers were oriented parallel to the bone axis and were in close contact with bone. Conclusions: Therefore, to achieve quadriceps muscle-to-bone reattachment, the BPC 157 therapy reversing course acts from the beginning, resolving an otherwise insurmountable deleterious course.
Mario Staresinic Igor Petrovic Tomislav Novinscak
Predrag Sikiric
We report complete transection of major muscle and the systemic peptide treatment that induces healing of quadriceps muscle promptly and then maintains the healing with functional restoration. Initially, stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419, PL-10, PLD-116, PL 14736 Pliva, Croatia; in trials for inflammatory bowel disease; wound treatment; no toxicity reported; effective alone without carrier) also superiorly accelerates the healing of transected Achilles tendon. Regularly, quadriceps muscle completely transected transversely 1.0 cm proximal to patella presents a definitive defect that cannot be compensated in rat. BPC 157 (10 mg, 10 ng, 10 pg/kg) is given intraperitoneally, once daily; the first application 30 min posttransection, the final 24 h before sacrifice. It consistently improves muscle healing throughout the whole 72-day period. Improved are: (i) biomechanic (load of failure increased); (ii) function (walking recovery and extensor postural thrust/motor function index returned toward normal healthy values); (iii) microscopy/immunochemistry [i.e., mostly muscle fibers connect muscle segments; absent gap; significant desmin positivity for ongoing regeneration of muscle; larger myofibril diameters on both sides, distal and proximal (normal healthy rat-values reached)]; (iv) macroscopic presentation (stumps connected; subsequently, atrophy markedly attenuated; finally, presentation close to normal noninjured muscle, no postsurgery leg contracture). Thus, posttransection healing-consistently improved-may suggest this peptide therapeutic application in muscle disorders. ß
Predrag Sikiric
Alenka Boban Blagaic Sanja Strbe
Sven Seiwerth
We highlight the particular aspects of the stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity (not destroyed in human gastric juice, native and stable in human gastric juice, as a cytoprotection mediator holds a response specifically related to preventing or recovering damage as such) and its possible relations with neurotransmitter activity. We attempt to resolve the shortage of the pleiotropic beneficial effects of BPC 157, given the general standard neurotransmitter criteria, in classic terms. We substitute the lack of direct conclusive evidence (i.e., production within the neuron or present in it as a precursor molecule, released eliciting a response on the receptor on the target cells on neurons and being removed from the site of action once its signaling role is complete). This can be a network of interconnected evidence, previously envisaged in the implementation of the cytoprotection effects, consistent beneficial particular evidence that BPC 157 therapy counteracts dopamine, serotonin, glutamate, GABA, adrenalin/noradrenalin, acetylcholine, and NO-system disturbances. This specifically includes counteraction of those disturbances related to their receptors, both blockade and over-activity, destruction, depletion, tolerance, sensitization, and channel disturbances counteraction. Likewise, BPC 157 activates particular receptors (i.e., VGEF and growth hormone). Furthermore, close BPC 157/NO-system relations with the gasotransmitters crossing the cell membrane and acting directly on molecules inside the cell may envisage particular interactions with receptors on the plasma membrane of their target cells. Finally, there is nerve-muscle relation in various muscle disturbance counteractions, and nerve-nerve relation in various encephalopathies counteraction, which is also exemplified specifically by the BPC 157 therapy application.
Ivica Premuzic Mestrovic
Ivan Smoday
Luka Kalogjera
Predrag Sikiric
We focused on the first demonstration that antiarrhythmics, particularly class II and class III antiarrhythmic and beta-blocker sotalol can induce severe occlusion/occlusion-like syndrome in rats. In this syndrome, as in similar syndromes with permanent occlusion of major vessels, peripheral and central, and other similar noxious procedures that severely disable endothelium function, the stable gastric pentadecapeptide BPC 157-collateral pathways activation, was a resolving therapy. After a high dose of sotalol (80 mg/kg intragastrically) in 180 min study, there were cause-consequence lesions in the brain (swelling, intracerebral hemorrhage), congestion in the heart, lung, liver, kidney, and gastrointestinal tract, severe bradycardia, and intracranial (superior sagittal sinus), portal and caval hypertension, and aortal hypotension, and widespread thrombosis, peripherally and centrally. Major vessels failed (congested inferior caval and superior mesenteric vein, collapsed azygos vein). BPC 157 therapy (10 μg, 10 ng/kg given intragastrically at 5 min or 90 min sotalol-time) effectively counteracted sotalol-occlusion/occlusion-like syndrome. In particular, eliminated were heart dilatation, and myocardial congestion affecting coronary veins and arteries, as well as myocardial vessels; eliminated were portal and caval hypertension, lung parenchyma congestion, venous and arterial thrombosis, attenuated aortal hypotension, and centrally, attenuated intracranial (superior sagittal sinus) hypertension, brain lesions and pronounced intracerebral hemorrhage. Further, BPC 157 eliminated and/or markedly attenuated liver, kidney, and gastrointestinal tract congestion and major veins congestion. Therefore, azygos vein activation and direct blood delivery were essential for particular BPC 157 effects. Thus, preventing such and similar events, and responding adequately when that event is at risk, strongly advocates for further BPC 157 therapy.
Edwin Lee Kailynd Burgess
Background: For years, the peptide Body Protection Compound 157 (BPC-157) has been used to treat partial muscle or tendon tears. Few studies on humans have been published, with none on the intravenous use of BPC-157 in humans. Objective: This IRB-approved study was conducted to assess whether intravenous BPC-157 is safe in humans. Methods: Baseline blood work and vital signs were obtained from 2 participants before and after each infusion. On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 3, fasting blood work and vital signs were repeated. Patients were questioned about any side effects at each appointment. Setting: This study was performed at a private clinic in Florida. Participants: Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial. Results: The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels. The BPC-157 peptide infusion was tolerated, with no side effects reported. Conclusion: Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated. The results of this pilot study showed the safety of BPC-157 in humans. Future studies are also needed to confirm the safety of intravenous BPC-157 in humans.
Edwin Lee Christopher Walker Bahram Ayadi
Context: Moderate to severe interstitial cystitis (also known as bladder pain syndrome) is a disabling disease with no effective treatment. Although pentosan polysulfate is an approved treatment for interstitial cystitis, some patients on this medication experience treatment failure after one year, and its long-term use has been linked to pigmentary maculopathy. The peptide Body Protective Compound 157 (BPC-157) is a possible treatment for interstitial cystitis but is currently not approved by the US Food and Drug Administration. Objective: To assess the safety and efficacy of BPC-157 manufactured by a 503A compounding pharmacy as a treatment for interstitial cystitis. Participants: Twelve women between the ages of 39 and 76 years with a mean age of 58.3 years participated in this trial at a private clinic. Of these, 10 were White, one was Asian, and one was Latina. None of the 12 women had responded to pentosan polysulfate. Methods: The women underwent cystoscopy and were treated with injections of the peptide BPC-157 (total of 10 mg) around the area of inflammation of the bladder during a single procedure. Global Response Assessment questionnaire was given to all the subjects to assess the efficacy of BPC-157. Results: Complete resolution of symptoms after one treatment was reported in 10 of 12 patients, who rated their success at 100%. The remaining 2 of 12 patients rated their success at 80%, with most symptoms resolved but about 20% of their symptoms lingering. No one dropped out of the study, and no adverse events were reported. This therapy was successful because all 12 patients scored a 5/5 on the Global Response Assessment. Conclusion: This is the first report of intravesical BPC-157 (10 mg) injection to help patients with moderate to severe interstitial cystitis who did not respond to pentosan polysulfate treatment.
Hsiu-Jung Liao
Hui-Ting Chen
Chih Hung Chang
Objects Osteoarthritis (OA) is a widespread degenerative joint condition commonly occurring in older adults. Currently, no disease-modifying drugs are available, and safety concerns associated with commonly used traditional medications have been identified. In this review, a significant portion of research in this field is concentrated on cartilage, aiming to discover methods to halt cartilage breakdown or facilitate cartilage repair. Methods Researchers have mainly investigated the cartilage, seeking methods to promote its repair. This review focuses on peptide-based molecules known for their ability to selectively bind to growth factor cytokines and components of the cartilage extracellular matrix. Results Chondroinductive peptides, synthetically producible, boast superior reproducibility, stability, modifiability, and yield efficiency over natural biomaterials. This review outlines a chondroinductive peptide design, molecular mechanisms, and their application in cartilage tissue engineering and also compares their efficacy in chondrogenesis in vitro and in vivo. Conclusions In this paper, we will summarize the application of peptides engineered to regenerate cartilage by acting as scaffolds, functional molecules, or both and discuss additional possibilities for peptides. This review article provides an overview of our current understanding of chondroinductive peptides for treating OA-affected cartilage and explores the delivery systems used for regeneration. These advancements may hold promise for enhancing or even replacing current treatment methodologies.
Mikalyn T. DeFoor
Travis Dekker
High‐level athletes and bodybuilders are constantly seeking novel therapies to enhance recovery and expedite return from injury—injectable peptides are a new and trending therapy that may be the wave of the future in the realm of regenerative medicine research in treating joint injuries and osteoarthritis. Very early in vivo research on pharmacokinetics indicates the possibility that body protection compound 157 (BPC‐157) is at the forefront of therapeutic peptides, with early demonstrations of this experimental peptide optimizing endurance training, metabolism, recovery, and tissue repair. Although unregulated and yet readily available for purchase over the internet, there is scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides in tendon, muscle, and cartilage injury. However, this has not slowed the recent exponential growth of the multi‐billion‐dollar industry in the development of therapeutic peptides. As orthopaedic surgeons and team physicians, we should stay up to date with the latest pharmacokinetic, safety, ethical, and legal profiles and regulations regarding synthetic peptide supplementation for injury recovery and sports performance optimization in our patients, from elite athletes to fitness fanatics, because they will continue to seek the latest and greatest in treatment options and will be approaching us with questions on their results, risks, and benefits.